{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-006898","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.897015+00:00","generated_at":"2026-06-18T00:22:06.168367+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties","bullets":["AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.","75% of DoD net sales under marketing agreement; rights revert if Buyer fails to commercialize by July 1, 2023.","Aguettant amendments: EUR 1.5M payment to AcelRx, termination of sales milestones, and supply restructuring.","Terminates Catalent site readiness and commercial supply agreements; equipment to be removed from Catalent's site."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-006898","json":"https://secwatch.observer/filing/0001437749-23-006898.json","markdown":"https://secwatch.observer/filing/0001437749-23-006898.md","text":"https://secwatch.observer/filing/0001437749-23-006898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/0001437749-23-006898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/acrx20230315_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:22:06.168367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}